Noteworthy, the activity of ADA (ADA1 and ADA2) changes during the interaction of tumor cells (triple-negative breast cancer) with lymphocytes, macrophages, and endothelial cells in vitro, providing unfavorable phenotype and contributing to cancer progression. The gene discussed is ADA; the disease is triple-negative breast carcinoma.